Amphastar Pharmaceuticals (AMPH) FCF Margin (2013 - 2026)

Amphastar Pharmaceuticals' FCF Margin history runs 14 years deep, the most recent figure standing at 25.51% for Q1 2026.

• On a quarterly basis, FCF Margin rose 917.0% year-over-year to 25.51% in Q1 2026; TTM through Mar 2026 was 19.02%, a 202.0% decrease from a year earlier, with the FY2025 full-year figure at 16.84%, down 670.0% from the prior year.
• FCF Margin improved to 25.51% in Q1 2026 per AMPH's latest filing, from 13.43% in the prior quarter.
• Across five years, FCF Margin topped out at 39.02% in Q2 2024 and bottomed at 3.7% in Q4 2024.
• The 5-year median for FCF Margin is 24.18% (2022), against an average of 21.58%.
• Biggest YoY gain for FCF Margin was 3396 bps in 2022; the steepest drop was 3294 bps in 2022.
• Year by year, FCF Margin stood at 9.92% in 2022, then jumped by 172 bps to 27.03% in 2023, then plunged by 114 bps to 3.7% in 2024, then jumped by 463 bps to 13.43% in 2025, then surged by 90 bps to 25.51% in 2026.
• Per Business Quant, the three latest AMPH FCF Margin figures stand at 25.51% (Q1 2026), 13.43% (Q4 2025), and 16.69% (Q3 2025).